NTRA - CMS coverage determination seen benefitting Natera - SVB Leerink

A local coverage determination ("LCD") published today by the Centers for Medicare and Medicaid Services ("CMS") and effective June 6 will provide a pathway to cover management of patients with organ transplants, benefitting Natera (NTRA), according to SVB Leerink.Analyst Puneet Souda writes this is a positive for Natera given the company's Prospera assay for transplant rejection.He adds that the LCD lays the ground for reimbursement of the overall transplant rejection biopsy market.Prospera is currently reimbursed for kidney transplant testing."This LCD...provides an avenue of coverage expansion into multiple solid organ transplants, which we believe creates upside to the $2B [total addressable market] (mgmt. estimate) realization timeline," Souda writes.Natera shares are down 1.7% to $107.79 in afternoon trading.

For further details see:

CMS coverage determination seen benefitting Natera - SVB Leerink